|

CHT101 Clinical Trials

2 actively recruiting trials

Pipeline

Phase 1: 2

Top Sponsors

  • Tianjin Medical University Cancer Institute and Hospital2

Indications

  • Cancer2
  • NHL (Non-Hodgkin Lymphoma)1
  • Relapsed / Refractory Solid Tumor1
  • Cutaneous T Cell Lymphoma (CTCL)1
  • Peripheral T Cell Lymphoma1

Other2 trials

A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors
Phase 1
A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.